Cohance Lifesciences Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) concerning its Pashamylaram manufacturing facility. The inspection outcome has been classified as Voluntary Action Indicated (VAI), signifying a positive resolution to the inspection process. This development marks the conclusion of the USFDA’s review for this facility.
USFDA Inspection Update for Pashamylaram Facility
Cohance Lifesciences Limited has provided an update regarding the inspection conducted by the United States Food and Drug Administration (USFDA) at its manufacturing facility located in Pashamylaram, Hyderabad. This facility holds the FEI No. 1000623515.
Positive Inspection Outcome
Following the inspection, the USFDA has issued the Establishment Inspection Report (EIR) for the Pashamylaram facility. The company announced that the inspection outcome has been classified as Voluntary Action Indicated (VAI). This classification suggests that the facility has addressed any identified concerns and is committed to implementing voluntary actions.
Inspection Conclusion
With the receipt of the EIR, Cohance Lifesciences confirms that the aforementioned USFDA inspection is now officially concluded. The company has requested stakeholders to take this information on record.
Source: BSE
